CONGRESS | #EHA2026 | POSTER Joshua Richter presents findings from a matching-adjusted indirect comparison of belantamab mafodotin plus bortezomib and dexamethasone (BVd; ESS = 47) vs teclistamab plus daratumumab (Tec-Dara; n = 291) for the treatment of RRMM. Following adjustment, BVd was associated with comparable OS, with RMST ratios of 1.04 at 1 year (p = 0.141), 1.04 at 2 years (p = 0.277), and 1.01 at 3 years (p = 0.801), and lower rates of treatment-emergent infections of any grade (81.3% vs 96.5%; p<0.001) vs Tec-Dara. These findings suggest BVd may offer a BCMA-directed treatment option for patients where infection risk is of particular concern. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @JoshuaRichterMD @TischCancer @IcahnMountSinai

Findings from a new study at @IcahnMountSinai suggests radiotherapy alters the tumor environment to support CAR T cell persistence via dendritic cells, potentially overcoming a key challenge in solid tumours. drugtargetreview.com/radioth… @Jalal_Ahmed @MiriamMerad

CONGRESS | #EHA2026 | POSTER Marina Kremyanskaya presents results from Arm 2 of the MANIFEST study, evaluating pelabresib added to ongoing ruxolitinib in suboptimal responders (N = 87). - Among 83 evaluable patients, 18.1% had SVR35 at Week 24 (16.4% TD; 21.4% non-TD); overall, 28.8% of patients had SVR35 at any time during treatment. - Median spleen response duration was 180.9 weeks. - At Week 24, 37.6% of evaluable patients (32/85) achieved TSS50 (36.2% TD; 40.7% non-TD). - Add-on pelabresib to ruxolitinib enabled 26.1% of TD patients to convert to TI. - The most common Grade ≥3 TEAEs were thrombocytopenia (39.1%), anemia (23.0%), and pneumonia (9.2%). Findings show that pelabresib added on to ongoing ruxolitinib demonstrated meaningful clinical benefit in a difficult-to-treat patient population, supporting further evaluation of pelabresib-containing combination approaches beyond JAK inhibition alone. Follow our live feed for more updates: loom.ly/N2uNnTk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MPN #MPNsm #MedicalCongress @MKremyanskaya @IcahnMountSinai @TischCancer

Study reported in @CellCellPress uncovers potential new biological mechanism linking aging, immune dysfunction, and Alzheimer's disease. pubmed.ncbi.nlm.nih.gov/4201… mountsinai.org/about/newsroo… @PapapetrouMDPhD, Samuele Marro, PhD, and colleagues @IcahnMountSinai

Check out our latest review👏! We dive deep into how cDC1s orchestrate anti-tumor immunity through cross-presentation, immune networking, and spatial organization.

Our goal is to prevent cancer using safe immunomodulatory therapies, perhaps even a pill, in people at risk. If we succeed, preventing cancer could become one of the greatest public health achievements of our generation.youtu.be/bVCE-7UUFGE?si=h-ga…

New from Josep Llovet @IcahnMountSinai and colleagues: Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement Nature Reviews Clinical Oncology rdcu.be/fnEGY

Nina Bhardwaj, MD, PhD, is on the Scientific Organizing Committee. @EdgarEGK is a speaker. Kelsey Monson, PhD, MS, is presenting a poster. @BhardwajLab @IcahnMountSinai

Getting an early look at our upcoming episode of The Moonlight Shift with the incredible @JoshuaRichterMD from @TischCancer and @MountSinaiNYC. We’re breaking down the latest in multiple myeloma and much more—full conversation drops this Thursday! Stay tuned. #Oncology #MMSM

Distinguishing occult blood loss from dilutional changes in serum hemoglobin concentration following IV fluid therapy ashpublications.org/bloodrci… Johnson Liu, MD, @IcahnMountSinai; David Mueller, MD

Submit an abstract by September 23 for the AACR Special Conference on Advances in the Pathogenesis and Immune Therapies of Liver Cancer (December 6-8; Austin, Texas), chaired by Richard S. Finn, Josep M. Llovet, and Jessica Zucman-Rossi. brnw.ch/21x361x #AACRliver26

.@MattGalsky discusses the emergence of ICIs the neoadjuvant setting of #bladdercancer. onclive.com/view/dr-galsky-o… @MountsinaiUro @IcahnMountSinai

Camilo Correa-Gallego, MD, @IcahnMountSinai, discusses recent medical advancements in targeted therapies that may improve treatment for #pancreaticcancer. youtube.com/live/m-7N9GbMrIM…

New paper from the lab. Using AI-guided modeling and experiments, we identified a hidden allosteric pocket in the cancer kinase PKMYT1. Led by @NHerrington24 in collaboration with @LazarusLab pubs.acs.org/doi/full/10.102…

beckershospitalreview.com/ph… @KarynAGoodman weighs in. #cancerclinicaltrials #cancerresearch

We look forward to hearing from Anil Rustgi, MD, @columbiacancer on June 9. "Molecular Regulation of Colon Cancer Pathogenesis" Hosted by Ramon Parsons, MD, PhD @IcahnMountSinai

Could COVID Increase Your Risk for HPV-Related Cancers? theflowspace.com/physical-he… via @thisisflowspace Dr. Stephanie Blank @IcahnMountSinai weighs in.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis. onclive.com/view/dr-mascaren…

An extremely eloquent and brave man spoke at our survivors event. The sentence he wrote everyday during CART was “ today is a good day”. He went on to say this was either meant to be an affirmation or an aspiration each day ! Always focus on the patients @TischCancer #mmsm

beckershospitalreview.com/ph… Deirdre Cohen, MD, @IcahnMountSinai, notes increased interest from patients with advanced #PancreaticCancer.